GS0976



NAME OF DRUG : GS0976

LABORATORY : GILEAD

STATUS AND ADVANCEMENT

Type of drug : ACC inhibitor

Clinical trials advancement : Ongoing Phase 2a

Estimated time to market : 104 months.

LABORATORY ABSTRACT ON THE DRUG

Acetyl-CoA carboxylase (ACC) is an enzyme with two isoforms (ACC1 and ACC2) that is involved in de novo lipogenesis (the synthesis of endogenous fatty acids) and the regulation of beta-oxidation (the process by which fatty acids are broken down at a cellular level). Inhibitors of ACC, therefore, have the potential to prevent production of new lipids within the liver and stimulate their breakdown. In animal models of fatty liver, ACC inhibition reduces hepatic fat content, inflammation and fibrosis (scarring), all of which are important hallmarks of NASH progression. NDI-010976 is a potent, liver-targeted, allosteric inhibitor of both ACC isoforms. NDI-010976 (now GS-0976) is an investigational therapy and has not been proven safe or efficacious.

HISTORY AND ANALYSIS

This medication was purchased by GILEAD from NIMBUS in their APOLLO program.

Comments have been made on the galenic kinetics of this drug which has a fairly short half-life in the body as shown in the following graph.

Plasma PK concentration

 

The results of the Phase 1 conducted by NIMBUS are available on the following poster

Nimbus Poster 

 

RECENT NEWS ON GS0976

2016-04-04 : GILEAD Announces Aquisition of Nimbus Therapeutic -Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases -

SOME PUBLICATIONS RELATED WITH GS0976

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH GS0976

October 2016 : NASH COMBOs ARE THE WAY


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016